NCT05889728 - Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

February 20, 2025

Study Completion Date

February 23, 2025

Conditions

Breast Cancer

Interventions

DRUG

[68Ga]GA-NeoB

Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).

Trial Locations (1)

2010

RECRUITING

St Vincent's Hospital, Sydney